WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Haghighatdoost F, Jabbari M, Hariri M
Semaglutide is the active ingredient in three medications: Ozempic, Wegovy, and Rybelsus
Weight loss can affect hormone levels, neurotransmitter function, and body image perception, all of which may influence mental health
Sulfur burps with diarrhea on GLP-1 medications Sulfur burps alone are unpleasant